National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
R01-AI127521
United States
Citation
Journal: Science / Year: 2021 Title: Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Authors: C Garrett Rappazzo / Longping V Tse / Chengzi I Kaku / Daniel Wrapp / Mrunal Sakharkar / Deli Huang / Laura M Deveau / Thomas J Yockachonis / Andrew S Herbert / Michael B Battles / Cecilia M ...Authors: C Garrett Rappazzo / Longping V Tse / Chengzi I Kaku / Daniel Wrapp / Mrunal Sakharkar / Deli Huang / Laura M Deveau / Thomas J Yockachonis / Andrew S Herbert / Michael B Battles / Cecilia M O'Brien / Michael E Brown / James C Geoghegan / Jonathan Belk / Linghang Peng / Linlin Yang / Yixuan Hou / Trevor D Scobey / Dennis R Burton / David Nemazee / John M Dye / James E Voss / Bronwyn M Gunn / Jason S McLellan / Ralph S Baric / Lisa E Gralinski / Laura M Walker / Abstract: The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. We employed a directed evolution approach to engineer three ...The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. We employed a directed evolution approach to engineer three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies for enhanced neutralization breadth and potency. One of the affinity-matured variants, ADG-2, displays strong binding activity to a large panel of sarbecovirus receptor binding domains and neutralizes representative epidemic sarbecoviruses with high potency. Structural and biochemical studies demonstrate that ADG-2 employs a distinct angle of approach to recognize a highly conserved epitope that overlaps the receptor binding site. In immunocompetent mouse models of SARS and COVID-19, prophylactic administration of ADG-2 provided complete protection against respiratory burden, viral replication in the lungs, and lung pathology. Altogether, ADG-2 represents a promising broad-spectrum therapeutic candidate against clade 1 sarbecoviruses.
History
Deposition
Dec 19, 2020
-
Header (metadata) release
Feb 10, 2021
-
Map release
Feb 10, 2021
-
Update
Mar 3, 2021
-
Current status
Mar 3, 2021
Processing site: RCSB / Status: Released
-
Structure visualization
Movie
Surface view with section colored by density value
In the structure databanks used in Yorodumi, some data are registered as the other names, "COVID-19 virus" and "2019-nCoV". Here are the details of the virus and the list of structure data.
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)
EMDB accession codes are about to change! (news from PDBe EMDB page)
The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
The EM Navigator/Yorodumi systems omit the EMD- prefix.
Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator
Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.
Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi